After completing this activity, the participant should be better able to:

• Review current research on the use of CDK 4/6 inhibitors for breast cancer patients, including  pre-clinical data, biomarker targets and sensitivity and resistance mechanisms
• Discuss the MOA of CDK 4/6 inhibitors
• Review clinical trial data on CDK 4/6 inhibitors, including efficacy and safety data
• Identify appropriate patient selection for the use of CDK 4/6 inhibitors
• Review the toxicity profiles of CDK 4/6 inhibitors
• Apply strategies to manage neutropenia and other adverse events
• Discuss existing and emerging clinical trial data associated with adverse events of combination  therapies using CDK 4/6 inhibitors
• Discuss ways to enhance clinician/patient communication to improve patient outcomes
• Apply shared decision-making strategies in the management of patients with breast cancer